Marinomed Biotech Investor Relations Material
Latest events
Q1 2024
Marinomed Biotech
H2 2024
16 Apr, 2025
H1 2024
27 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Marinomed Biotech AG
Access all reports
Marinomed Biotech AG is an Austrian biotechnology company specializing in antiviral and immunology products. The company develops therapies based on proprietary technology platforms for treating respiratory and ocular diseases. It focuses on both prescription and over-the-counter formulations with applications in global healthcare markets. The company is headquartered in Korneuburg, Austria, and its shares are listed on the VSE.
Latest articles
)
Global Doughmination: Breaking Down Domino's Pizza
Inside the rise of Domino's Pizza: how franchising, delivery control, and supply chain mastery built one of the world's most efficient food empires.
18 Jul 2025
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
Ticker symbol
MARI
Country
🇦🇹 Austria